The South American country Colombia has an attractive pharmaceutical market that should appeal to multinational companies looking for emerging growth opportunities.
Colombia is experiencing increasing demand for pharmaceutical products as a result of the country's positive economic landscape, booming population and government policies to broaden access to medicines through the expansion in health insurance and affordable drug coverage, according to a new report from Decision Resources Group.
Colombia also has a thriving generic sector, as a result of government cost-containment efforts that offers growth potential for both domestic and multinational pharmaceutical companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze